Amgen Wins Supreme Court Review Of EPO Securities Fraud Class Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.